Target therapies completely changed the clinical approach in EGFR mutated and ALK rearranged non-small cell lung cancer, ensuring these patients exceptional outcomes with a better toxicity profile compared to conventional chemotherapy. In recent years, beyond EGFR and ALK alterations, new data are emerging about less common alterations, new drugs have been already approved and others agents have been recently investigated or are currently under investigation. In this review we will discuss some uncommon alterations in non-small cell lung cancer such as ROS1, BRAF, RET, HER2, NTRK, MET and other targets that are in an early evaluation phase. We will summarize the characteristics of patients harboring these alterations, the already approved or under investigation therapies and the related resistance mechanisms.

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake / A. De Toma, G. Lo Russo, D. Signorelli, F. Pagani, G. Randon, G. Galli, A. Prelaj, R. Ferrara, C. Proto, M. Ganzinelli, N. Zilembo, F. de Braud, M.C. Garassino. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 160:(2021 Apr), pp. 103299.1-103299.15. [10.1016/j.critrevonc.2021.103299]

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake

G. Lo Russo;G. Randon;F. de Braud
Penultimo
;
2021

Abstract

Target therapies completely changed the clinical approach in EGFR mutated and ALK rearranged non-small cell lung cancer, ensuring these patients exceptional outcomes with a better toxicity profile compared to conventional chemotherapy. In recent years, beyond EGFR and ALK alterations, new data are emerging about less common alterations, new drugs have been already approved and others agents have been recently investigated or are currently under investigation. In this review we will discuss some uncommon alterations in non-small cell lung cancer such as ROS1, BRAF, RET, HER2, NTRK, MET and other targets that are in an early evaluation phase. We will summarize the characteristics of patients harboring these alterations, the already approved or under investigation therapies and the related resistance mechanisms.
Non-small cell lung cancer; Resistance mechanism; Target therapy; Uncommon alterations; Anaplastic Lymphoma Kinase; Humans; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms
Settore MED/06 - Oncologia Medica
apr-2021
mar-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1040842821000871-main.pdf

solo utenti autorizzati

Tipologia: Publisher's version/PDF
Dimensione 1.12 MB
Formato Adobe PDF
1.12 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/908352
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact